3 steps for TEPEZZA care coordination:
DEVELOP
communication
channel for patient’s
TED team
ESTABLISH roles
and responsibilities
for documentation
and monitoring
DISCUSS patient
progress and
results of treatment
Before beginning TEPEZZA, be aware that insurance payors may require the Clinical Activity Score (CAS),*† thyroid labs, and/or documentation of previously tried medications (such as steroids) for treatment approval. It is recommended that you download the Clinical Documentation Tearpadto appropriately document inflammatory signs and symptoms of TED, such as CAS. It is important to ask patients if they have, or have ever had, any of these CAS symptoms.2-4 It may even be helpful to ask your patient to share a photo of how he or she used to look.
Download the TEPEZZA Access Roadmap, or speak with your Amgen
Representative for more
detailed information on the steps to get your patients started on TEPEZZA.
Amgen believes cost should never stop someone from getting the medicine they
need. Support for your patients is available from Amgen By Your Side.
During treatment with TEPEZZA, my eye bulging became less and less. My double vision went away. The redness was gone. And the pain and swelling under my eyes improved.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.
Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.
Please see Full Prescribing Information for more information.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4%